Business Context and Reporting Period
This Form 8-K was filed on September 21, 2022, by Mana Capital Acquisition Corp. (the "Registrant"), a special purpose acquisition company (SPAC). The filing discloses a material event regarding the proposed business combination between Mana Capital and Cardio Diagnostics, Inc. ("Cardio"). Upon completion of the merger, Mana Capital will change its name to Cardio Diagnostics Holdings, Inc.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period. The document focuses on regulatory disclosures and corporate developments rather than financial performance data.
Material Changes and Events
- Patent Issuance: On September 21, 2022, the U.S. Patent and Trademark Office issued a patent to the University of Iowa Research Foundation (UIRF). This patent is exclusively licensed to Cardio Diagnostics.
- Inventors: The patent was co-invented by Cardio founders Meesha Dogan, Ph.D., and Robert Philibert, MD Ph.D., who serve as the Company's Chief Executive Officer and Chief Medical Officer, respectively.
- Merger Status: The filing reiterates the May 27, 2022 Merger Agreement between Mana Capital and Cardio, noting that the business combination is subject to the satisfaction or waiver of certain conditions.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the anticipated financial impacts and timing of the Business Combination. Management cautions that actual results may differ materially from expectations due to significant risks and uncertainties, including:
- Failure to obtain stockholder approval or satisfy closing conditions.
- Legal proceedings or unsolicited offers that could interfere with the transaction.
- Inability to list the post-acquisition company on the Nasdaq Stock Market.
- Disruption of current plans and operations during the merger process.
- Challenges in market penetration, intellectual property protection, and managing growth.
- Impact of the COVID-19 pandemic and changes in applicable laws or regulations.
Investors are directed to review the Form S-4 registration statement for detailed information regarding the proxy solicitation and the proposed transaction.
Investor Verification Checklist
- Verify the status of the Form S-4 registration statement and the definitive proxy statement for the proposed Business Combination.
- Confirm the specific terms of the exclusive license agreement between Cardio Diagnostics and the University of Iowa Research Foundation regarding the newly issued patent.
- Review the "Risk Factors" section in Mana Capital's Form S-1, Form 10-K, and Form S-4 for a comprehensive list of uncertainties.
- Monitor announcements regarding the satisfaction of closing conditions required to finalize the merger.